AMIC licenses radiogel technology for rad therapy
Advanced Medical Isotope Corporation (AMIC), a producer and distributor of medical isotopes, has obtained an exclusive license to eight patents for injectable radiogel technology for use in high-dose radiation therapy. The license was granted by Battelle pursuant to an option between Battelle and AMIC announced in February 2011.
The agreement grants AMIC an exclusive license to make, have made, use and sell a radiogel system including an injectable, water-based biodegradable polymer that delivers Yttrium-90 microspheres into tumor tissues. The technology warms to body temperature after injection and then polymerizes into a lattice that traps the Yttrium-90 microspheres in place.
The injectable radiogel also may be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors and pancreatic cancer, AMIC said.
The agreement grants AMIC an exclusive license to make, have made, use and sell a radiogel system including an injectable, water-based biodegradable polymer that delivers Yttrium-90 microspheres into tumor tissues. The technology warms to body temperature after injection and then polymerizes into a lattice that traps the Yttrium-90 microspheres in place.
The injectable radiogel also may be administered transdermally or intraoperatively when treating solid tumors that cannot be removed safely by surgical excision, such as inoperable liver cancer, brain tumors, head and neck tumors, kidney tumors and pancreatic cancer, AMIC said.